Peptide immunotherapies in Type 1 diabetes: Lessons from animal models

Current Medicinal Chemistry

Volumn 18, Issue 4, 2011, Pages 577-586

  Fierabracci, A ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Animal models; Autoimmunity; Disease prevention; Peptide immunotherapy; Type 1 diabetes

Indexed keywords

1040 P31 PROTEIN; ANTIDIABETIC AGENT; AUTOANTIGEN; B 9 23; CHOLERA TOXIN B GADIII; DIAMYD; GAD 509 528; GAD 524 538; GAD 530 543; GAD 65 217 236; GAD 65 290 309; GLATIRAMER; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65; GLUTAMATE DECARBOXYLASE 67; HSP60 P277; INSB 15 23; INSB 9 23; INSULIN; INTERLEUKIN 10; ISLET SPECIFIC GLUCOSE 6 PHOSPHATASE CATALYTIC SUBUNIT RELATED PROTEIN; L 7 24; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROINSULIN; SOLUBLE IA G7 IMMUNOGLOBULIN DIMER; STREPTOZOCIN; TETRAMER; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANTIBODY TITER; ARTICLE; BB DP RAT; DISEASE MODEL; ENTERITIS; GRAFT REJECTION; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INSULIN DEPENDENT DIABETES MELLITUS; LIVER FIBROSIS; MOUSE STRAIN; MULTIPLE SCLEROSIS; NONHUMAN; NONOBESE DIABETIC MOUSE; RAT STRAIN; REPEATED DRUG DOSE; SINGLE DRUG DOSE; UVEORETINITIS;

ANIMALS; DIABETES MELLITUS, TYPE 1; DISEASE MODELS, ANIMAL; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOTHERAPY; INSULIN; MICE; PEPTIDE FRAGMENTS;

EID: 79851472626     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711794480230     Document Type: Article

References (62)

1. Fierabracci, A.; Bottazzo, G. F. The continuous discovery of autoantigens in endocrine organ-specific autoimmunity: do they help us to understand pathogenesis? Springer Semin. Immunopathol, 2002, 24, 243-259. (Pubitemid 35447455)
2. Fierabracci, A. Unravelling autoimmune pathogenesis by screening random peptide libraries with human sera. Immunol. Lett, 2009, 124, 35-43.
3. Fierabracci, A. Unravelling the role of infectious agents in the pathogenesis of human autoimmunity: the hypothesis of the retroviral involvement revisited. Curr. Mol. Med., 2009, 9, 1024-1033.
4. Bluestone, J. A.; Herold, K.; Eisenbarth, G. Genetics, pathogenesis and clinical interventions in Type 1 diabetes. Nature, 2010, 464, 1293-1300.
5. Taplin, C. E.; Barker, J. M. Autoantibodies in Type 1 diabetes. Autoimmunity, 2008, 41, 11-18.
6. Wang, B.; Tisch, R. Parameters influencing antigen-specific immunotherapy for Type 1 diabetes. Immunol. Res., 2008, 41, 175-187.
7. Luo, X.; Herold, K. C.; Miller, S. D. Immunotherapy of Type 1 diabetes: where are we and where should be going? Immunity, 2010, 32, 488-499.
8. McDevitt, H. Specific antigen vaccination to treat autoimmune disease. Proc. Natl. Acad. USA, 2004, 101, 14627-14630. (Pubitemid 39346734)
9. Gregori, S.; Battaglia, M.; Roncarolo, M. G. Re-establishing immune tolerance in type 1 diabetes via regulatory T cells. Novartis Found. Symp., 2008, 292, 174-183.
10. Cheţa, D. Animal models of Type 1 (Insulin-Dependent) Diabetes mellitus. J. Pediatr. Endocrinol. Metab., 1998, 11, 11-19. (Pubitemid 28110748)
11. Banting, F. G.; Best, C. H. The internal secretion of the pancreas. Lab. Clin. Med, 1922, 7, 251-266.
12. Lam-Tse, W. K.; Lernmark, A.; Drexhage, H. A. Animal models of endocrine/organ-specific autoimmune diseases: do they really help us to understand human autoimmunity? Springer Semin. Immunopathol, 2002, 24, 297-321. (Pubitemid 35447458)
13. Stone M. A.; Camosso-Stefinovic, J.; Wilkinson, J.; de Lusignan, S.; Hattersley, A. T.; Khunti, K. Incorrect and incomplete coding and classification of diabetes: a systematic review. Diabet. Med., 2010, 27, 491-497.
14. Tisch, R.; Yang, X. D.; Singer, S. M.; Liblau, R. S.; Fugger, L.; McDevitt, H. O. Immune response to glutamic acid decarboxylase correlates with insulitis in non-obese diabetic mice. Nature, 1993, 366, 72-75. (Pubitemid 23345239)
15. Yoon, J. W.; Yoon, C. S.; Lim, H. W.; Huang, Q. Q.; Kang, Y.; Pyun K. H.; Hirasawa, K.; Sherwin, R. S.; Jun, H. S. Control of autoimmune diabetes in NOD mice by GAD expression or suppression in beta cells. Science, 1999, 284, 1183-1187. (Pubitemid 29288411)
16. Tisch, R.; Wang, B.; Serreze, D. V. Induction of glutamic acid decarboxylase 65-specific Th2 cells and suppression of autoimmune diabetes at late stages of disease is epitope dependent. J. Immunol, 1999, 163, 1178-1187. (Pubitemid 29352732)
17. Tisch, R.; Wang, B.; Atkinson M. A.; Serreze, D. V.; Friedline, R. A glutamic acid decarboxylase 65-specific Th2 cell clone immunoregulates autoimmune diabetes in nonobese diabetic mice. J. Immunol, 2001, 166, 6925-6936. (Pubitemid 32467240)
18. Tarbell, K. V.; Yamazaki, S.; Olson, K.; Toy, P.; Steinman, R. M. CD5+ CD4+T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med, 2004, 199, 1467-1477. (Pubitemid 38780402)
19. Chen, G.; Han, G.; Feng, J.; Wang, J.; Wang, R.; Xu, R.; Shen, B.; Qian, J.; Li, Y. Glutamic acid decarboxylase-derived epitopes with specific domains expand CD4+ CD25+ regulatory T cells. PloS One, 2009, 4, e7034.
20. Clare-Saltzer, M. J.; Brooks, J.; Chai, A.; Van Herle, K.; Anderson, C. Prevention of diabetes in nonobese diabetic mice by dendritic cell transfer. J. Clin. Invest, 1992, 90, 741-748.
21. Lo, J.; Peng, R. H.; Barker, T.; Xia, C.-Q.; Clare-Salzler, M. J. Peptide-pulsed immature dendritic cells reduce response to β cell target antigens and protect NOD recipients from Type 1 diabetes. Ann. N. Y. Acad. Sci., 2006, 1079, 153-156. (Pubitemid 44968716)
22. Wang, H.; Yang, J.; Jin, L.; Feng, J.; Lu, Y.; Sun, Y.; Li, T.; Cao, R.; Wu, J.; Fan, H.; Liu, J. Immunotherapy of autoimmune diabetes by nasal administration of tandem glutamic acid decarboxylase 65 peptides. Immunol. Invest., 2009, 38, 690-703.
23. Li, L.; Yi, Z.; Wang, B.; Tisch, R. Suppression of ongoing T cellmediated autoimmunity by peptide-MHC class II dimer vaccination. J. Immunol, 2009, 183, 4809-4816.
24. Casares, S.; Hurtado, A.; McEvoy, R. C.; Sarukhan, A.; von Boehmer, H.; Brumeanu, T. D. Down-regulation of diabetogenic CD4+ T cells by a soluble dimeric peptide-MHC class II chimera. Nat. Immunol, 2002, 3, 383-391. (Pubitemid 34308627)
25. Lin, M.; Stoica-Nazarov, C.; Surfs, J.; Kehl, M.; Bona, C.; Olsen, C.; Brumeanu, T. D.; Casares, S. Reversal of type 1 diabetes by a new MHC II-peptide chimera: "Single-epitope-mediated suppression" to stabilize a polyclonal autoimmune T-cell process. Eur. J. Immunol, 2010, 40, 2277-2288.
26. Nakayama, M.; Abiru, N.; Moriyama, H.; Babaya, N.; Liu, E.; Miao, D.; Yu, L.; Wegmann, D. R.; Hutton, J. C.; Elliott, J. F.; Eisenbarth, G. S. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature, 2005, 435, 220-223. (Pubitemid 40685949)
27. Kent, S. C.; Chen, Y.; Bregoli, L.; Clemmings, S. M.; Kenyon, N. S.; Ricordi, C.; Hering, B. J.; Hafler, D. A. Expanded T cells from pancreatic lymph nodes of type 1 diabetic subjects recognize an insulin epitope. Nature, 2005, 435, 224-228. (Pubitemid 40685950)
28. Muir, A.; Peck, A.; Clare-Salzler, M.; Song, Y. H.; Cornelius, J.; Luchetta, R.; Krischer, J.; Maclaren, N. Insulin immunization of nonobese diabetic mice induces a protective insulitis characterized by diminished intraislets interferon-gamma transcription. J. Clin. Invest., 1995, 95, 628-634.
29. Chen, W.; Bergerot, I.; Elliott, J. F.; Harrison, L. C.; Abiru, N.; Eisenbarth, G. S.; Delovitch, T. L. Evidence that a peptide spanning the B-C Junction of proinsulin is an early autoantigen epitope in the pathogenesis of type 1 diabetes. J. Immunol, 2001, 167, 4926-4935. (Pubitemid 33009722)
30. Daniel, D.; Wegmann, D. R. Intranasal administration of insulin peptide B: 9-23 protects NOD mice from diabetes. Ann. N Y Acad. Sci., 1996, 778, 371-372.
31. Martinez, N. R.; Augstein, P.; Moustakas, A. K.; Papadopoulos, G. K.; Gregori, S.; Adorini, L.; Jackson, D. C.; Harrison, L. C. Disabling an integral CTL epitope allows suppression of autoimmune diabetes by intranasal proinsulin peptide. J. Clin Invest, 2003, 111, 1365-1371. (Pubitemid 36554707)
32. Arai, T.; Moriyama, H.; Shimizu, M.; Sasaki, H.; Kishi, M.; Okumachi, Y.; Yasuda, H.; Hara, K.; Yokono, K.; Nagata, M. Administration of a determinant of preproinsulin can induce regulatory T cells and suppress anti-islet autoimmunity in NOD mice. Clin. Immunol, 2010, 136, 74-82.
33. Bresson, D.; Togher, L.; Rodrigo, E.; Chen, Y.; Bluestone, J. A.; Herold, K. C.; von Herrath, M. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J. Clin. Invest, 2006, 116, 1371-1381.
34. Haase, C.; Yu, L.; Eisenbarth, G.; Markholst, H. Antigendependent immunotherapy of non-obese diabetic mice with immature dendritic cells. Clin. Exp. Immunol, 2010, 160, 331-339.
35. Atkinson, M. A.; Holmes, L. A.; Scharp, D. W.; Lacy, P. E.; Maclaren, N. K. No evidence for serological autoimmunity to islet cell heat shock proteins in insulin-dependent diabetes. J. Clin. Invest, 1991, 87, 721-724.
36. Elias, D.; Cohen, I. R. Treatment of autoimmune diabetes and insulitis in NOD mice with heat shock protein 60 peptide p277. Diabetes, 1995, 44, 1132-1138.
37. Liang, J.; Aihua, Z.; Yu, W.; Yong, L.; Jingjing, L. HSP65 serves as an immunogenic carrier for a diabetogenic peptide p277 inducing anti-inflammatory immune response in NOD mice by nasal administration. Vaccine, 2010, 28, 3312-3317.
38. Tarbell, K. V.; Yamazaki, S.; Olson, K.; Toy, P.; Steinman, R. M. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med., 2004, 199, 1467-1477. (Pubitemid 38780402)
39. Miller, S. D.; Turley, D. M.; Podojil, J. R. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat. Rev. Immunol., 2007, 7, 665-677. (Pubitemid 47327394)
40. Fife, B. T.; Guleria, I.; Gubbels Bupp, M.; Eagar, T. N.; Tang, Q., Bour-Jordan, H.; Yagita, H.; Azuma, M.; Sayegh, M. H.; Bluestone, J. A. Insulin-induced remission in new-onset NOD mice is maintained by the PD-1-PD-L1 pathway. J. Exp. Med., 2006, 203, 2732-2747.
41. Santamaria, P. Genetic and therapeutic control of diabetogenic CD8+ T cells. Novartis Found. Symp., 2008, 292, 130-136.
42. Han, B.; Serra, P.; Amrani, A.; Yamanouchi, J.; Marée, A. F.; Edelstein-Keshet, L.; Santamaria, P. Prevention of diabetes by manipulation of anti-IGRP autoimmunity: high efficiency of a low affinity peptide. Nat. Med., 2005, 11, 645-652. (Pubitemid 40868305)
43. Altman, J. D.; Moss, P. A.; Goulder, P. J.; Barouch, D. H.; McHeyzer-Williams, M. G.; Bell, J. I.; McMichael, A. J.; Davis, M. M. Phenotypic analysis of antigen-specific T lymphocytes. Science, 1996, 274, 94-96. (Pubitemid 26332731)
44. Vincent, B. G.; Young, E. F.; Buntzman, A. S.; Stevens, R.; Kepler, T. B.; Tisch, R. M.; Frelinger, J. A.; Hess, P. R. Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in NOD diabetic mice. J. Immunol., 2010, 184, 4196-4204.
45. Amrani, A.; Verdaguer, J.; Serra, P.; Tafuro, S.; Tan, R.; Santamaria, P. Progression of autoimmune diabetes driven by avidity maturation of a T cell population. Nature, 2000, 406, 739-742.
46. Gebe, J. A.; Masewicz, S. A.; Kochik, S. A.; Reijonen, H.; Nepom, G. T. Inhibition of altered-peptide ligand-mediated antagonism of human GAD65-responsive CD4+ T cells by non-antagonizable T cells. Eur. J. Immunol., 2004, 34, 3337-3345. (Pubitemid 40012153)
47. Cui, G.; Zhang, Y.; Gong, Z.; Zhang, J. Z.; Zang, Y. Q. Induction of CD4+CD25+Foxp3+ regulatory T cell response by glatiramer acetate in type 1 diabetes. Cell Res., 2009, 19, 574-583.
48. Roep, B. O.; Atkinson, M. Animal models have little to teach us about Type 1 diabetes: 1. In support of this proposal. Diabetologia, 2004, 47, 1650-1656. (Pubitemid 40022396)
49. Bieg, S.; Hanlon, C.; Hampe, C. S.; Benjamin, D.; Mahoney, C. P. GAD65 and insulin B chain peptide (9-23) are not primary autoantigens in the type 1 diabetes syndrome of the BB rat. Autoimmunity, 1999, 31, 15-24. (Pubitemid 32454567)
50. Elias, D.; Cohen, I. R. The hsp60 peptide p277 arrests the autoimmune diabetes induced by the toxin streptozotocin. Diabetes, 1996, 45, 1168-1172. (Pubitemid 26296314)
51. Roep, B. O. Are insights gained from NOD mice sufficient to guide clinical translation? Another inconvenient truth. Ann. NY. Acad. Sci., 2007, 1103, 1-10. (Pubitemid 46791118)
52. Giuliani, L.; Mele, R.; Di Giovine, M.; Altieri, L.; Crinò, A.; Ravà, L.; Fierabracci, A. Detection of GAD65 autoreactive T-cells by HLA class I tetramers in type 1 diabetic patients. J. Biomed. Biotechnol, 2009, 2009, 576219.
53. Raz, I.; Eldor, R.; Naparstek, Y. Immune modulation for prevention of type 1 diabetes mellitus. Trends Biotechnol, 2005, 23, 128-134. (Pubitemid 40269845)
54. Eckenrode, S. E.; Ruan, Q.-G.; Collins, CD.; Yang, P.; McIndoe, R. A.; Muir, A.; She, J. X. Molecular pathways altered by insulin B9-23 immunisation. Ann. N. Y. Acad. Sci., 2004, 1037, 175-185. (Pubitemid 40299763)
55. Peakman, M.; von Herrath, M. Antigen-specific immunotherapy for Type 1 diabetes: maximizing the potential. Diabetes, 2010, 59, 2087-2093.
56. Pozzilli, P.; Leslie, R. D. New prospects for immunotherapy at diagnosis of type 1 diabetes. Diabetes Metab. Res. Rev., 2009, 25, 299-301.
57. Ludviggson, J. Therapy with GAD in diabetes. Diabetes Metab. Res. Rev., 2009, 25, 307-315.
58. Raz, I.; Elias, D.; Avron, A.; Tamir, M.; Metzger, M.; Cohen, I. R. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet, 2001, 358, 1749-1753. (Pubitemid 33152998)
59. Schloot, N. C.; Meierhoff, G.; Lengyel, C.; Vándorfi, G.; Takács, J.; Pánczél, P.; Barkai, L.; Oroszlán, T.; Kovács, P.; Siito, G.; Battelino, T.; Hosszufalusi, N.; Jermendy, G. Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials. Diabetes Metab. Res. Rev, 2007, 23, 276-285. (Pubitemid 46851468)
60. Ludvigsson, J.; Faresjo, M.; Hjorth, M.; Axelsson, S.; Chérami, M.; Pihl, M.; Vaarala, O.; Forsander, G.; Ivarsson, S.; Johansson, C.; Lindh, A.; Nilsson, N. O.; Aman, J.; Ortqvist, E.; Zerhouni, P.; Casas, R. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N. Engl. J. Med, 2008, 359, 1909-1920.
61. Agardh, C.-D.; Cilio, CM.; Lethagen, A.; Lynch, K.; Leslie, R. D. G.; Palmér, M.; Harris, R. A.; Robertson, J. A.; Lernmark, Å. Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes. J. Diabetes Complications, 2005, 19, 238-246. (Pubitemid 40910206)
62. Kappos, L.; Comi, G.; Panitch, H.; Oger, J.; Antel, J.; Conlon, P.; Steinman, L. Induction of a non-encephalitogenic type 2 T helpercell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in placebo-controlled, randomized phase II trial. The altered peptide ligand in relapsing MS study group. Nat. Med, 2000, 10, 1176-1182.